(Shi Mengzhu, a reporter from the Health Client of the Peoples Daily) "The pharmaceutical industry develops in an orderly and healthy manner on the full chain, which is an important part of supporting the strategy of healthy China." On November 7th, in the seventhAt the theme meeting of the full chain of China International Import Expo to support the biomedical industry innovation and development theme conference, the chairman of the Shanghai Medical Association said that under the guidance and policy guidance of the national medical development full chainAmong them, the strength of their respective industries is used to strengthen cooperation and innovation to promote the development of the industry.
The chairman of the Shanghai Medical Association, Yan Jinglei.The organizers picture
邬 主 主 said that in the form and content of academic exchanges, it is necessary to adapt to and support the development of the entire biomedical industry.In terms of external expansion, it is also hoped that the Shanghai Medical Association will be built into a platform -type society, so that the platform will not only serve medical staff, but also contribute to industrial development.
Professor Wu Ming, a professor at the Department of Health Policy and Management, School of Public Health, Peking University,
Wu Ming, a professor at the Department of Health Policy and Management of the School of Public Health of Peking University, said that more than a dozen links such as R & D, approval, and patent protection will eventually affect patients dignity and actual use of pharmaceutical products and actual use.On the whole, the front -end policy is favorable, but there are many policy links in the back -end. How to balance the interests and goals of all parties in the policy formulation need to consider it.Promoting the development of pharmaceutical innovation, it is necessary to carry out systematic design based on the perspective of the full policy chain.For example, Wu Ming, a public hospital is one of the largest terminals used in innovative products, and is also an executive agency for many departmental policies. It is facing a series of situations such as high management costs and some policies. It has affected the admission and use of innovative pharmaceutical products to a certain extent.She believes that innovation incentives should be designed as one of the policy goals in all aspects of the policy chain to improve the synergy of inspiration innovation in various aspects of policy chain.
"The medical industry is related to good health, life safety, but also the peoples longing for a better life. We hope to further promote global medicine through an open platform like the Expo.Enterprises expand the Chinese market, strengthen innovation research and development and international cooperation, and actively integrate into the global supply chain and industrial chain.
